- Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection
-
Kim DY
- KMID: 1792354
- Gut Liver.
- 2014 Jul;8(4):335-336.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Peginterferon-alpha and Ribavirin Combination Therapy in Chronic Hepatitis C
-
Han KH, Yoon YH
- KMID: 760535
- Korean J Hepatol.
- 2004 Jun;10(2):81-87.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients
-
Lee YJ
- KMID: 1073296
- Korean J Hepatol.
- 2008 Dec;14(4):443-445.
- doi: 10.3350/kjhep.2008.14.4.443
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C
-
Lee HJ, Eun JR, Choi JW, Kim KO, Moon HJ
- KMID: 1073329
- Korean J Hepatol.
- 2008 Mar;14(1):46-57.
- doi: 10.3350/kjhep.2008.14.1.46
BACKGROUND/AIMS: This study compared the efficacy and safety of combined peginterferon alfa (PEG-IFN) and ribavirin with that of combined interferon alpha (IFN-alpha) and ribavirin, according to the treatment duration... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection
-
Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, Park ET, Lee YJ, Lee SH, Seol SY
- KMID: 1381462
- Korean J Hepatol.
- 2008 Sep;14(3):318-330.
- doi: 10.3350/kjhep.2008.14.3.318
BACKGROUND/AIMS: We assessed the efficacy and safety of pegylated interferon (peginterferon) plus ribavirin and identified the predictors of a sustained virologic response (SVR) in Korean patients with chronic hepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation
-
Kim BK, Kwon SY, Ko SY, Choe WH, Lee CH, Han HS, Chang SH
- KMID: 1073304
- Korean J Hepatol.
- 2008 Dec;14(4):519-524.
- doi: 10.3350/kjhep.2008.14.4.519
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
-
Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima , Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 2412052
- Gut Liver.
- 2016 Jul;10(4):617-623.
- doi: 10.5009/gnl15193
BACKGROUND/AIMS: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using... -
- CITED
-
- Close
- SHARE
-
- Close
- 24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia
-
Moon SS, Kang HG, Seo JA, Jung EU, Lee SH, Park SJ, Lee YJ, Seol SY
- KMID: 1775876
- Korean J Gastroenterol.
- 2010 Jul;56(1):33-38.
- doi: 10.4166/kjg.2010.56.1.33
BACKGROUND/AIMS: The standard treatment for chronic hepatitis C infected with hepatitis C virus (HCV) genotype 1 is a combination of pegylated interferon alfa and ribavirin over a 48 weeks period.... -
- CITED
-
- Close
- SHARE
-
- Close
- Short-term Therapy with Pegylated Interferon plus Ribavirin for the Chronic Hepatitis C Genotype 2 Patients
-
Jung EU, Park JH, Pae KI, Kang SW, Park SJ, Jee SR, Park ET, Lee YJ, Lee SH, Seol SY
- KMID: 760735
- Korean J Hepatol.
- 2007 Sep;13(3):341-348.
- doi: 10.3350/kjhep.2007.13.3.341
BACKGROUND/AIMS: The standard treatment for chronic hepatitis C patients infected with HCV genotype-2 is a combination of pegylated interferon alfa and ribavirin over a 24 week period. It is... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
-
Kwon JH, Bae SH, Choi JY, Yoon SK, Byun KS, Paik SW, Lim YS, Lee HC, Han KH, Lee KS
- KMID: 1717943
- Korean J Intern Med.
- 2009 Sep;24(3):203-211.
- doi: 10.3904/kjim.2009.24.3.203
BACKGROUND/AIMS: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
-
Jung CH, Um SH, Kim TH, Yim SY, Suh SJ, Yim HJ, Seo YS, Choi HS, Chun HJ
- KMID: 2412080
- Gut Liver.
- 2016 Sep;10(5):808-817.
- doi: 10.5009/gnl15360
BACKGROUND/AIMS: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction of a Null Response to Pegylated Interferon alpha-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
-
Wada Y, Tamai H, Kawashima , Shingaki N, Mori Y, Kawaguchi , Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 1792366
- Gut Liver.
- 2014 Jul;8(4):421-427.
BACKGROUND/AIMS: The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon alpha-2b plus ribavirin therapy in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Peginterferon Alfa-2a plus Ribavirin for Initial Treatment of Chronic Hepatitis C in Korea
-
Lee H, Choi MS, Paik SW, Kim JH, Kim DY, Lee JH, Koh KC, Yoo BC, Rhee JC, Song SM
- KMID: 760628
- Korean J Hepatol.
- 2006 Mar;12(1):31-40.
BACKGROUND/AIMS: Combination therapy with peginterferon and ribavirin is a standard therapy for western patients with chronic hepatitis C; however, its efficacy remains unclear in East Asian patients. We evaluated... -
- CITED
-
- Close
- SHARE
-
- Close
- A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C
-
Kim MN, Yoon KT, Park JY, Kim DY, Ahn SH, Chon CY, Han KH
- KMID: 1384057
- Korean J Hepatol.
- 2009 Dec;15(4):496-503.
- doi: 10.3350/kjhep.2009.15.4.496
BACKGROUND/AIMS: The standard therapy for patients with genotype 1 chronic hepatitis C (CHC) is a combination of peginterferon and ribavirin for 48 weeks. However, the most appropriate duration of treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study
-
Kim JI, Kim SH, Lee BS, Lee HY, Lee TH, Kang YW, Lee HI, Kim AN, Nam SW, Park BC, Chae HB, Kim SB, Song IH, Park JY, Kim HS
- KMID: 1073301
- Korean J Hepatol.
- 2008 Dec;14(4):493-502.
- doi: 10.3350/kjhep.2008.14.4.493
BACKGROUNDS/AIMS: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
-
Shin SR, Kim YS, Lim YS, Lee JS, Lee JW, Kim SM, Jeong SH, Sohn JH, Lee MS, Park SH
- KMID: 2412194
- Gut Liver.
- 2017 Mar;11(2):270-275.
- doi: 10.5009/gnl16163
BACKGROUND/AIMS: Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and... -
- CITED
-
- Close
- SHARE
-
- Close
